D.E. Shaw & Co’s Ionis Pharmaceuticals IONS Stock Holding History

D.E. Shaw & Co’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,900	Closed	-$355K	–	5072
2021 Q2	$355K	Hold	8,900	–	–	﹤0.01%	4195
2021 Q1	$400K	Hold	8,900	–	–	﹤0.01%	3606
2020 Q4	$503K	Hold	8,900	–	–	﹤0.01%	3384
2020 Q3	$422K	Hold	8,900	–	–	﹤0.01%	3300
2020 Q2	$525K	Buy	+8,900	New	+$495K	﹤0.01%	3342
2016 Q2	–	Sell	-31,500	Closed	-$1.28M	–	3416
2016 Q1	$1.28M	Buy	31,500 +22,100	+235%	+$898K	﹤0.01%	2188
2015 Q4	$582K	Hold	9,400	–	–	﹤0.01%	2989
2015 Q3	$380K	Sell	9,400 -30,000	-76%	-$1.55M	﹤0.01%	3235
2015 Q2	$2.27M	Buy	39,400 +10,200	+35%	+$649K	﹤0.01%	2099
2015 Q1	$1.86M	Sell	29,200 -8,400	-22%	-$570K	﹤0.01%	2071
2014 Q4	$2.32M	Hold	37,600	–	–	﹤0.01%	2158
2014 Q3	$1.46M	Sell	37,600 -7,800	-17%	-$276K	﹤0.01%	2481
2014 Q2	$1.56M	Buy	45,400 +7,800	+21%	+$246K	﹤0.01%	2527
2014 Q1	$1.63M	Sell	37,600 -28,100	-43%	-$1.36M	﹤0.01%	2586
2013 Q4	$2.62M	Hold	65,700	–	–	﹤0.01%	2264
2013 Q3	$2.47M	Hold	65,700	–	–	﹤0.01%	2238
2013 Q2	$1.76M	Buy	+65,700	New	+$1.4M	﹤0.01%	2250

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co's IONS Position: Q1 2026 in Review

D.E. Shaw & Co increased its Ionis Pharmaceuticals (IONS) stake by 29% in Q1 2026, buying an estimated $7.64M and bringing the position to 429,599 shares worth $32.3M. The position accounts for 0.02% of the portfolio, ranked #888.

D.E. Shaw & Co first reported a position in IONS in Q2 2013 and has held it in 45 quarters since. The position peaked at $49.7M in Q3 2019. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

D.E. Shaw & Co held 429,599 shares of Ionis Pharmaceuticals worth $32.3M as of Q1 2026.
D.E. Shaw & Co bought 96,796 Ionis Pharmaceuticals shares in Q1 2026, an estimated $7.64M.
Ionis Pharmaceuticals made up 0.02% of D.E. Shaw & Co's portfolio in Q1 2026, its #888 holding.
D.E. Shaw & Co first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
D.E. Shaw & Co's Ionis Pharmaceuticals position peaked at $49.7M in Q3 2019.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.